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Other names: BRCA1-associated RING domain 
protein 1 
Location: 2q35 
Local order: Antiparallel. 
DNA/RNA 
Description 
The gene spans 81 kb, composed of 11 exons. 
Alternatively spliced isoforms are identified. 
Insert known isoforms: 
 
 
BARD1beta (rat testis); 
BARD1delta (rat ovarian cancer cells); 
BARD1delta (HeLa); 
BARD1delta (rat ovarian cancer cells). 
Transcription 
Transcription start is 100 bp upstream of first ATG of 
the BARD1 ORF. There a two 3’ends reported and 
possibly two alternative polyadenylation sites. BARD1 
is expressed in most proliferative tissues. Highest 
expression in testis and spleen. No expression the 
central nervous system. 
Pseudogene 




BARD1 structure is presented with RING finger (green) ankyrin repeats (ANK, blue) and BRCT domains (red). Positions of introns (in) 
are indicated. Structures of splice variants are shown for BARD1beta from the rat (Feki et al., 2004), BARD1delta (Feki et al., 2005; 
Tsuzuki et al., 2006). 
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Mouse and human BARD1 protein sequences are shown schematically. RING finger domains (gren), Ankyrin repeats (ANK, blue), 
BRCT domains (red), nulear localization signals (light blue). Homology between human and mouse BARD1 is indicated in perentage of 




Human BARD1 777 amino acids; Structural motifs: 
RING, 5 Ankyrin repeats, 2 BRCT domains. 
Expression 
In the mouse BARD1 is expressed in most proliferative 
tissues. Highest expression in testis and spleen, no 
expression in nervous system. 
During mouse development BARD1 is expressed in 
early embryogenesis and declines after day 9. 
Localisation 
During S-phase BARD1 localizes to nuclear dots. 
Partially, BARD1 is also localized to the cytoplasm in 
response to stress. 
Function 
BARD1 functions as heterodimer with BRCA1 as 
ubiquitin ligase. Several targets of the BARD1-BRCA1 
ubiquitin ligase have been identified and suggest its 
implication in DNA repair, polyadenylation, cell cycle 
control, and mitosis. 
BARD1 acts as inducer of apoptosis, independently of 
BRCA1, by binding to p53, and by binding to the stre s  
response kinase DNA-PK, facilitating p53 
phosphorylation and stabilization. Thus BARD1 acts as 
signaling molecule from genotoxic stress towards p53-
dependent apoptosis. 
Homology 
BARD1 is homologous to BRCA1, regarding the N-
terminal RING finger and the C-terminal BRCT 
domains. Weak homology between BARD1 and 
BRCA1 can be found throughout exon 1 to exon 4. and 
from exon 7 through exon 11, with conserved intron-
exon junctions. 
Mutations 
Note: Several mutations of BARD1 have been 
identified in breast and ovarian cancers. Three 
mutations have been reported associated with inherited 
predisposition to breast and ovarian cancer. 
Germinal 
Germline mutations were reported for C557S and 
Q564H. 
Somatic 
Several somatic mutation were reported in addition o 





BARD1 mutations associated with cancer. Small mutations are not unambiguously identified as cancer causing mutations, long arrows 
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Implicated in 
Breast and/or ovarian cancer 
Note: Upregulated expression of truncated BARD1 in 
epithelial cancers. 
Prognosis 
Upregulated BARD1 is correlated with poor prognosis 






No fusion proteins reported. 
Ovarian cancer 
Prognosis 
Upregulated BARD1 is correlated with poor prognosis 




No fusion proteins reported. 
Lung cancer 
Prognosis 
Upregulated BARD1 is correlated with poor prognosis 




No fusion proteins reported. 
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